O. Imeci , H. Asci , S. Asci , M.A. Sevuk , H.S. Sarikaya , O. Ozmen
{"title":"“达格列净通过可能参与IL-17A/GSK3β信号通路和炎症细胞因子的调节来减轻脂多糖诱导的神经炎症”。","authors":"O. Imeci , H. Asci , S. Asci , M.A. Sevuk , H.S. Sarikaya , O. Ozmen","doi":"10.1016/j.ejphar.2025.177913","DOIUrl":null,"url":null,"abstract":"<div><h3>Background</h3><div>Neuroinflammation drives neuronal degeneration and cognitive decline through various mechanisms. Interleukin (IL)-17A, secreted by Th17 cells, activates glycogen synthase kinase 3 beta (GSK3β), worsening neuroinflammation via the nuclear factor kappa B (NF-κB) pathway. Dapagliflozin (DPG), a sodium/glucose cotransporter 2 inhibitor with neuroprotective effects, reduces oxidative stress, apoptosis, and inflammation. This study examines DPG's molecular impact on neuroinflammation in an LPS-induced rat model.</div></div><div><h3>Methods</h3><div>The experiment was designed with four groups as control, lipopolysaccharide (LPS) (5 mg/kg, intraperitoneal), LPS + DPG (10 mg/kg via oral gavage), and DPG, with a total of thirty-two female Wistar Albino rats. After five days of treatment, the rats were euthanized. Brain and cerebellum tissues were gathered for biochemical analysis to examine oxidative stress parameters spectrophotometrically; histological and immunostaining analysis focusing on caspase-9 (Cas-9), NF-κB, and IL-10 immunoexpressions, and genetic analysis as IL-17A, GSK3β, IL-6, and cyclooxygenase 2 gene expressions by qRT-PCR.</div></div><div><h3>Results</h3><div>Histopathological evaluation revealed hyperemia, edema, mild degeneration, neuronal death, and modest gliosis in the LPS group. Increment of Cas-9 and NF-κB immunoexpressions, oxidative stress parameters, and the mRNA expressions of all four genes, in addition to the decrement of IL-10 and total antioxidant status, have been observed. DPG treatment significantly reversed all these findings and protected the neuronal tissues against LPS-induced substantial neuronal damage.</div></div><div><h3>Conclusion</h3><div>In conclusion, DPG may exert neuroprotective effects through the involvement of the IL-17A/GSK3β pathway and reduction of oxidative stress; however, further studies are needed to clarify causal mechanisms and broader anti-inflammatory actions.</div></div>","PeriodicalId":12004,"journal":{"name":"European journal of pharmacology","volume":"1003 ","pages":"Article 177913"},"PeriodicalIF":4.2000,"publicationDate":"2025-07-02","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":"0","resultStr":"{\"title\":\"Dapagliflozin mitigates lipopolysaccharide-induced neuroinflammation through potential involvement of the IL-17A/GSK3β signaling pathway and modulation of inflammatory cytokines\",\"authors\":\"O. Imeci , H. Asci , S. Asci , M.A. Sevuk , H.S. Sarikaya , O. Ozmen\",\"doi\":\"10.1016/j.ejphar.2025.177913\",\"DOIUrl\":null,\"url\":null,\"abstract\":\"<div><h3>Background</h3><div>Neuroinflammation drives neuronal degeneration and cognitive decline through various mechanisms. Interleukin (IL)-17A, secreted by Th17 cells, activates glycogen synthase kinase 3 beta (GSK3β), worsening neuroinflammation via the nuclear factor kappa B (NF-κB) pathway. Dapagliflozin (DPG), a sodium/glucose cotransporter 2 inhibitor with neuroprotective effects, reduces oxidative stress, apoptosis, and inflammation. This study examines DPG's molecular impact on neuroinflammation in an LPS-induced rat model.</div></div><div><h3>Methods</h3><div>The experiment was designed with four groups as control, lipopolysaccharide (LPS) (5 mg/kg, intraperitoneal), LPS + DPG (10 mg/kg via oral gavage), and DPG, with a total of thirty-two female Wistar Albino rats. After five days of treatment, the rats were euthanized. Brain and cerebellum tissues were gathered for biochemical analysis to examine oxidative stress parameters spectrophotometrically; histological and immunostaining analysis focusing on caspase-9 (Cas-9), NF-κB, and IL-10 immunoexpressions, and genetic analysis as IL-17A, GSK3β, IL-6, and cyclooxygenase 2 gene expressions by qRT-PCR.</div></div><div><h3>Results</h3><div>Histopathological evaluation revealed hyperemia, edema, mild degeneration, neuronal death, and modest gliosis in the LPS group. Increment of Cas-9 and NF-κB immunoexpressions, oxidative stress parameters, and the mRNA expressions of all four genes, in addition to the decrement of IL-10 and total antioxidant status, have been observed. DPG treatment significantly reversed all these findings and protected the neuronal tissues against LPS-induced substantial neuronal damage.</div></div><div><h3>Conclusion</h3><div>In conclusion, DPG may exert neuroprotective effects through the involvement of the IL-17A/GSK3β pathway and reduction of oxidative stress; however, further studies are needed to clarify causal mechanisms and broader anti-inflammatory actions.</div></div>\",\"PeriodicalId\":12004,\"journal\":{\"name\":\"European journal of pharmacology\",\"volume\":\"1003 \",\"pages\":\"Article 177913\"},\"PeriodicalIF\":4.2000,\"publicationDate\":\"2025-07-02\",\"publicationTypes\":\"Journal Article\",\"fieldsOfStudy\":null,\"isOpenAccess\":false,\"openAccessPdf\":\"\",\"citationCount\":\"0\",\"resultStr\":null,\"platform\":\"Semanticscholar\",\"paperid\":null,\"PeriodicalName\":\"European journal of pharmacology\",\"FirstCategoryId\":\"3\",\"ListUrlMain\":\"https://www.sciencedirect.com/science/article/pii/S0014299925006673\",\"RegionNum\":3,\"RegionCategory\":\"医学\",\"ArticlePicture\":[],\"TitleCN\":null,\"AbstractTextCN\":null,\"PMCID\":null,\"EPubDate\":\"\",\"PubModel\":\"\",\"JCR\":\"Q1\",\"JCRName\":\"PHARMACOLOGY & PHARMACY\",\"Score\":null,\"Total\":0}","platform":"Semanticscholar","paperid":null,"PeriodicalName":"European journal of pharmacology","FirstCategoryId":"3","ListUrlMain":"https://www.sciencedirect.com/science/article/pii/S0014299925006673","RegionNum":3,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":null,"EPubDate":"","PubModel":"","JCR":"Q1","JCRName":"PHARMACOLOGY & PHARMACY","Score":null,"Total":0}
Dapagliflozin mitigates lipopolysaccharide-induced neuroinflammation through potential involvement of the IL-17A/GSK3β signaling pathway and modulation of inflammatory cytokines
Background
Neuroinflammation drives neuronal degeneration and cognitive decline through various mechanisms. Interleukin (IL)-17A, secreted by Th17 cells, activates glycogen synthase kinase 3 beta (GSK3β), worsening neuroinflammation via the nuclear factor kappa B (NF-κB) pathway. Dapagliflozin (DPG), a sodium/glucose cotransporter 2 inhibitor with neuroprotective effects, reduces oxidative stress, apoptosis, and inflammation. This study examines DPG's molecular impact on neuroinflammation in an LPS-induced rat model.
Methods
The experiment was designed with four groups as control, lipopolysaccharide (LPS) (5 mg/kg, intraperitoneal), LPS + DPG (10 mg/kg via oral gavage), and DPG, with a total of thirty-two female Wistar Albino rats. After five days of treatment, the rats were euthanized. Brain and cerebellum tissues were gathered for biochemical analysis to examine oxidative stress parameters spectrophotometrically; histological and immunostaining analysis focusing on caspase-9 (Cas-9), NF-κB, and IL-10 immunoexpressions, and genetic analysis as IL-17A, GSK3β, IL-6, and cyclooxygenase 2 gene expressions by qRT-PCR.
Results
Histopathological evaluation revealed hyperemia, edema, mild degeneration, neuronal death, and modest gliosis in the LPS group. Increment of Cas-9 and NF-κB immunoexpressions, oxidative stress parameters, and the mRNA expressions of all four genes, in addition to the decrement of IL-10 and total antioxidant status, have been observed. DPG treatment significantly reversed all these findings and protected the neuronal tissues against LPS-induced substantial neuronal damage.
Conclusion
In conclusion, DPG may exert neuroprotective effects through the involvement of the IL-17A/GSK3β pathway and reduction of oxidative stress; however, further studies are needed to clarify causal mechanisms and broader anti-inflammatory actions.
期刊介绍:
The European Journal of Pharmacology publishes research papers covering all aspects of experimental pharmacology with focus on the mechanism of action of structurally identified compounds affecting biological systems.
The scope includes:
Behavioural pharmacology
Neuropharmacology and analgesia
Cardiovascular pharmacology
Pulmonary, gastrointestinal and urogenital pharmacology
Endocrine pharmacology
Immunopharmacology and inflammation
Molecular and cellular pharmacology
Regenerative pharmacology
Biologicals and biotherapeutics
Translational pharmacology
Nutriceutical pharmacology.